logo

For the Inventor, By the Inventor

Princeton Junction, NJ, United States of America

Chia-Yu Huang

This inventor holds 12 USPTO granted patents and 2 published patent applications and 4 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Venenum Biodesign, LLC, Schering Corporation, Pharmacopeia Inc.. Active years: 2002-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Chia-Yu Huang. Retrieved from https://idiyas.com/inventor/chia-yu-huang

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 12 

% Patents Active = 50.0

 

Average Co-Inventor Count = 8.0

ph-index = 4

Forward Citations = 58(Granted Patents)


Location History:

  • Plainsboro, NJ (US) (2002 - 2008)
  • West Windsor, NY (US) (2010)
  • Princeton Junction, NJ (US) (2010 - 2022)
  • West Windsor, NJ (US) (2011 - 2023)

Company Filing History:

goldMedal5 out of 8 
 
Venenum Biodesign, LLC
 patents
silverMedal4 out of 1,829 
 
Schering Corporation
 patents
bronzeMedal2 out of 101 
 
Pharmacopeia Inc.
 patents
4. 1 out of 248 
 
Cephalon, Inc.
 patents
5. 1 out of 2,405 
 
Merck Sharp + Dohme Corp.
 patents
6. 1 out of 52 
 
Pharmacopeia Drug Discovery, Inc.
 patents
7. 1 out of 28 
 
Schering-Plough Corporation
 patents
where one patent can have more than one assignee

Years Active: 2002-2023

Loading Chart...
Loading Chart...
Areas of Expertise:
TREX1 Inhibitors
TGR5 Agonists
Alpha2C Adrenoreceptor Agonists
Spirocyclic Piperidine Derivatives
Antitumor Agents
Farnesyl Protein Transferase
Histamine-3 Receptor Ligands
Functionally Selective Agonists
12 patents (USPTO):Explore Patents
1. 11583538 - Substituted pyrrolo[1,2-a]pyrazines and pyrrolo[1,2-a][1,4]diazepines as TREX1 inhibitors (2023-02-21),
2. 11306098 - Substituted pyrrolo[1,2-a]pyrazines and pyrrolo[1,2-a][1,4]diazepines as TREX1 inhibitors (2022-04-19),
3. 11236055 - Non-systemic TGR5 agonists (2022-02-01),
4. 11161864 - Sting agonists (2021-11-02),
5. 10654834 - Non-systemic TGR5 agonists (2020-05-19),
6. 8513232 - Substituted spirocyclic piperidine derivatives as histamine-3 (H3) receptor ligands (2013-08-20),
7. 8501747 - Functionally selective alpha2C adrenoreceptor agonists (2013-08-06),
8. 7985748 - ALPHA2C adrenoreceptor agonists (2011-07-26),
9. 7803828 - Functionally selective alpha2C adrenoreceptor agonists (2010-09-28),
10. 7700592 - α2C adrenoreceptor agonists (2010-04-20),
11. 7342016 - Farnesyl protein transferase inhibitors as antitumor agents (2008-03-11),
12. 6432959 - Inhibitors of farnesyl-protein transferase (2002-08-13),

Title: Chia-Yu Huang: Innovator in Pharmaceutical Chemistry

Introduction

Chia-Yu Huang is a prominent inventor based in Princeton Junction, NJ (US), known for her significant contributions to pharmaceutical chemistry. With a total of 12 patents to her name, she has made remarkable strides in the field of medicinal compounds.

Latest Patents

Her latest patents include innovative compounds such as substituted pyrrolo[1,2-a]pyrazines and pyrrolo[1,2-a][1,4]diazepines, which serve as TREX1 inhibitors. These compounds are designed to modulate the TREX1 protein, making them potential medicaments for treating or preventing disorders related to TREX1 inhibition. The detailed formulations of these compounds are defined in her patents, showcasing her expertise in creating effective pharmaceutical solutions.

Career Highlights

Chia-Yu Huang has worked with notable companies in the industry, including Venenum Biodesign, LLC and Schering Corporation. Her experience in these organizations has allowed her to develop and refine her innovative ideas, contributing to advancements in drug development.

Collaborations

Throughout her career, she has collaborated with esteemed colleagues such as Kevin D McCormick and Christopher W Boyce, further enhancing her research and development efforts.

Conclusion

Chia-Yu Huang's work exemplifies the impact of innovation in pharmaceutical chemistry, particularly through her patents that address critical health issues. Her contributions continue to influence the field and pave the way for future advancements.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…